Aging Code Summit

ACS 2026 returns to Cambridge, bringing together top minds to discuss basic scientific, translational, and financial advancements in aging.

Aging research is entering a new phase.

For years, the field has been driven by foundational discoveries across epigenetics, immune aging, mitochondrial biology, and neurodegeneration. Today, those insights are beginning to move beyond the lab and into therapeutics, diagnostics, and real clinical strategies.

At the same time, advances in biomarker development, longitudinal data collection, and AI-driven analysis are reshaping how aging is measured, tracked, and ultimately intervened on.

Aging Code Summit is designed around this shift.

Now in its second year and becoming one of Longevity Global’s flagship events, the summit brings together a highly curated group of ~300 attendees across science, biotech, pharma, and investment.

The focus is not on broad, high-level discussion. It is on what is actually working, what is still unclear, and what it takes to move aging biology into practice.

Check out this year's lineup HERE.

What Will Be Covered

Day 1: Science → Translation → Capital

Day 1 is grounded in the biology of aging and how it connects to real intervention and company formation.

Discussions will focus on:

• Core mechanisms driving aging and age-related disease, including areas like mitochondrial dysfunction, immune aging, and epigenetic regulation
• How these biological insights are being translated into therapeutics, biomarkers, and measurable interventions
• The current state of aging clocks and other approaches to quantifying aging
• What it actually takes to build in longevity, from early validation to infrastructure and execution
• How investors and pharmaceutical companies are evaluating the space, including where there is real traction and where skepticism remains

The goal is to connect foundational science directly to how programs and companies are being built today.

Day 2: Clinical → Deployment → Scale

Day 2 shifts to how aging science is applied in real-world systems and where the field is heading next.

Discussions will focus on:

• How aging biology is being integrated into clinical and patient-facing models
• The role of longitudinal biomarker tracking and continuous lab testing in preventative care
• How real-world data is beginning to inform intervention strategies and clinical trial design
• The challenges and opportunities in scaling these models across broader populations
• The role of AI and data infrastructure in both discovery and clinical deployment

Day 2 also features:

• Live pitch competition finals for Seed and Series A companies building in aging and longevity - APPLY TO PITCH HERE
• Direct interaction between founders, investors, and pharma teams evaluating the space

Who This Is For

This is a space for people actively building in the field:

• Scientists advancing aging biology and age-related disease research
• Founders developing therapeutics, platforms, and diagnostics
• Investors exploring where the field is heading
• Pharma and BD teams evaluating new approaches
• Operators working across data, infrastructure, and clinical systems
• Physicians integrating aging biomarkers and preventative approaches into care
• Science-driven wellness and nutrition practitioners

The format is intentionally designed to prioritize meaningful interaction over scale, creating an environment where conversations go deeper and connections are more relevant.

What This Becomes

The next phase of aging research will not be defined by individual discoveries alone, but by how effectively those discoveries are translated into real systems, companies, and clinical impact.

That requires alignment across science, infrastructure, and capital.

Aging Code Summit is designed to bring those pieces together in one place, with the people who are actually building in the field.